This webinar discusses the current landscape of cytokine-based cancer immunotherapy, primarily the gamma chain family of cytokines, and looks ahead at the future developments within the field.
Tumor-associated enzymes can diminish or even negate the immune system’s ability to fight off cancerous cells by making subtle but damaging structural changes to anti-cancer antibodies.
For the body to defend and fight against cancer, immune cells must recognize, engage, destroy and ultimately remove unwanted tumor cells. Understanding these processes at the cellular level is central to identifying and validating new immunotherapy approaches.
Alongside intense efforts to exploit T-cells as immunotherapies for cancer (e.g. checkpoint inhibitors, CAR-T, T-cell metabolism), researchers are increasingly considering other immune cell types for novel targets. One example is the enhancement of macrophage function via inhibitors of CD47 “don’t-eat-me” signalling proteins, enabling tumour cells to evade clearance by neighbouring phagocytes (Kim et al, 2012, Leukemia 26, 2538–2545).
In this exclusive webcast of our workshop held at IMMUNOLOGY 2017™ in Washington, D.C., learn how to add real-time visualization and analysis of immune cell cultures to your in vitro assay toolkit for immunology research.